Is elimination of vertical transmission of HIV in high prevalence settings achievable?

Ameena Goga and colleagues argue that more realistic targets are needed to maintain momentum on reducing vertical transmission in countries with a high HIV prevalence.

The idea of eliminating infectious diseases from society dates to the 18th century, when Edward Jenner envisioned elimination of smallpox through widespread vaccination. By 1997, the difference between control, eradication, and elimination had been defined (box 1). Of the perinatally acquired infections, only tetanus, HIV, and syphilis have been targeted for elimination.

In 2011, the joint United Nations Programme on HIV/AIDS (UNAIDS) launched a global plan to eliminate new HIV infections among children by 2015 and to keep mothers with HIV infection from transmitting to their children by 2015. UNAIDS highlighted the vertical transmission of HIV (also known as mother-to-child transmission of HIV) in the 22 countries where 90% of the world’s pregnant women with HIV reside (global plan priority countries). UNAIDS reported in 2016 that 1.2 million new HIV infections in children were averted in the 21 global plan priority countries in sub-Saharan Africa between 2009 and 2015. Seven of these countries had reduced new HIV infections by more than 70% since 2009 (Burundi 84%, Malawi 71%, Mozambique 75%, Namibia 79%, South Africa 84%, and Swaziland 80%). UNAIDS highlighted the urgent need for action to end the AIDS epidemic by 2030 as part of the sustainable development goals.

What is meant by eliminating HIV?

In 2012, a global consultation of over 70 experts, including country programme managers, agreed that one of the criteria to validate elimination of vertical transmission of HIV as a public health problem is a paediatric HIV incidence of ≤50 per 100,000 live births (box 2). This paediatric case rate was chosen because it was consistent with previous WHO elimination initiatives and expert consensus was that it was achievable (personal communication, C Hayashi, Unicef).

The decision to focus on eliminating rather than eradicating vertical transmission was taken because optimal interventions to prevent vertical HIV transmission are not 100% effective. Eliminating a disease as a public health problem is a powerful motivator and one that can be embraced without overpromising or setting programmes up for failure.

In 2014, the WHO published criteria to validate that a country has eliminated vertical transmission of HIV (box 2). The WHO guidance, updated in 2017, recommends that each country should have adequate national monitoring and evaluation systems in place and adequate laboratory systems within the public and private sectors to assist with measurement.

As of October 2017, 10 countries or territories where elimination of vertical transmission of HIV has been validated are Cuba, Thailand, Armenia, Belarus, Anguilla, Montserrat, Cayman Islands, Bermuda, Antigua and Barbuda, and St Kitts and Nevis. However, none of these countries has a high HIV prevalence and none is a global plan priority country. In 2017, the concept of pre-elimination was introduced to recognise progress in preventing vertical transmission of HIV in high burden countries. To achieve validation for pre-elimination, ≥90% coverage across all three process indicator targets is needed and the rate of vertical transmission must be below 5%. Importantly, there is no new target transmission case rate to qualify for pre-elimination. The complexity of vertical transmission of HIV means that achieving the child case rate to validate elimination will continue to be challenging in priority countries. Here we suggest how interest in the aspirational goal of eliminating vertical transmission of HIV can be maintained even though the case rate target seems unattainable in the short to medium term.

What makes eliminating vertical transmission so complex?

A comparison with neonatal tetanus, one of the three neonatal diseases targeted for elimination, shows the complexity of eliminating vertical transmission of HIV (see supplementary table on bmj.com). Neonatal tetanus is a non-transmissible disease caused by Clostridium tetani, a ubiquitous neurotoxin producing bacterium that contaminates infants’ umbilical cords through normal childbirth without medical intervention. The case rate is an aspirational goal that may not be realised in the short to medium term in many high HIV prevalence settings. To maintain momentum, policy makers should identify and monitor process indicators that increase opportunities for HIV prevention.

KEY MESSAGES

- An HIV infection case rate of ≤50/100,000 live births is needed to validate a country’s elimination of vertical transmission as a public health problem
- The case rate heavily depends on maternal HIV prevalence, making elimination targets challenging in high prevalence settings even with low vertical transmission rates
- The case rate is an aspirational goal that may not be realised in the short to medium term in many high HIV prevalence settings
- To maintain momentum, policy makers should identify and monitor process indicators that increase opportunities for HIV prevention

Box 1: Definitions of disease elimination

- **Control**—The reduction of disease incidence, prevalence, morbidity, or mortality to a locally acceptable level as a result of deliberate efforts. Continued intervention measures are required to maintain the reduction (eg, diarrhoeal disease)
- **Elimination of disease**—Reduction of a specified disease to zero incidence in a defined geographical area as a result of deliberate efforts. Continued intervention measures are required (eg, neonatal tetanus)
- **Elimination of infections**—Reduction to zero incidence of infection caused by a specific agent in a defined geographical area as a result of deliberate efforts. Continued measures are needed to prevent re-establishment of transmission (eg, measles, polio)
- **Eradication**—Permanent zero worldwide incidence of infections with a specific agent as a result of deliberate efforts. Intervention measures are no longer needed (eg, smallpox)
- **Extinction**—The specific agent no longer exists in nature or in the laboratory
Vertical transmission of HIV is more complex, cord contamination. Practices and proper cord care to prevent pregnancy alongside hygienic delivery prevented by immunising women during
Consequently, neonatal tetanus is easily on maternal infection or drug therapy.
A single route, which does not depend primary prevention of HIV before, during,
to the end of breastfeeding. This includes requiring intervention from preconception
of disease. In contrast, children mainly acquire HIV infection from their mothers
during pregnancy, labour, delivery, or breastfeeding. HIV may not be detectable
for up to six weeks after infection, and it can take months to progress to AIDS.
C tetani bacteria are transmitted by a single route, which does not depend on maternal infection or drug therapy. Consequently, neonatal tetanus is easily prevented by immunising women during pregnancy alongside hygienic delivery practices and proper cord care to prevent cord contamination. Preventing vertical transmission of HIV is more complex, requiring intervention from preconception to the end of breastfeeding. This includes primary prevention of HIV before, during,
and after pregnancy; prevention of unwanted or unplanned pregnancies; early initiation of antiretroviral therapy (ART); retention on ART for women with HIV; and retesting women without HIV to detect new infections early. Early antenatal care is also important to optimise general care, monitoring of maternal viral load, safe delivery practices, and infant postexposure prophylaxis.

What makes the target case rate hard to achieve?
Despite the complexity of reducing vertical transmission, many countries with a high HIV prevalence have made good progress. However, they remain far from achieving a case rate of ≤50 new HIV infections per 100 000 live births at the end of breastfeeding, which is needed to validate elimination of vertical transmission.

In 2016–17, antenatal HIV prevalence in South Africa was roughly 32% and the national intratertiary vertical transmission of HIV rate was 0.9% at delivery. This corresponds to a HIV case rate at delivery of 288/100 000 live births (0.2% multiplied by 100 000 live births (to calculate number of babies exposed to HIV) multiplied by 0.9%). This value is well above the target of ≤50 babies and is a measure of intratertiary HIV transmission, not transmission at the end of breastfeeding.

At the provincial level, across South Africa, intratertiary vertical transmission rates ranged from 0.6% to 1.3%, but new HIV infection case rates ranged from 168/100 000 to 325/100 000 live births. UNAIDS 2017 models estimate that vertical transmission rates range from 4% (Namibia and Uganda) to 21% (Angola) in the 22 global plan priority countries but case rates range from 85/100 000 live births in Burundi to 12000/100 000 in Swaziland.

Maintaining momentum in the elimination agenda
Given the substantial challenges in reaching the case rate target to achieve validation for elimination of vertical transmission of HIV, we suggest a greater focus on and recognition of process targets to maintain momentum. Policy makers and managers could track additional process indicators that increase opportunities for HIV prevention during the pre-elimination period. These can be tracked locally, regionally, and nationally through quality improvement processes that have been shown to be effective in routine settings.

Data dashboards that track vertical transmission of HIV indicators have been associated with improved programme performance at national and facility levels. These dashboards use red, amber, and green colour coding to illustrate achievement of targets. We suggest that policy makers or managers issue annual or biennial recognition for selected indicator measurements in relation to global goals. These selected indicators could be expanded beyond the current pre-elimination list to include those that measure increased coverage and uptake of maternal and child healthcare, on the assumption that increased coverage will reduce unhygienic delivery practices. Neonatal tetanus progresses quickly and can take 3–21 days between infection and the appearance of disease. In contrast, children mainly acquire HIV infection from their mothers during pregnancy, labour, delivery, or breastfeeding. HIV may not be detectable for up to six weeks after infection, and it can take months to progress to AIDS.

Vertical transmission of HIV indicators have been associated with improved programme performance at national and facility levels. These dashboards use red, amber, and green colour coding to illustrate achievement of targets. We suggest that policy makers or managers issue annual or biennial recognition for selected indicator measurements in relation to global goals. These selected indicators could be expanded beyond the current pre-elimination list to include those that measure increased coverage and uptake of maternal and child healthcare, on the assumption that increased coverage will reduce
Box 4: Potential indicators to track progress in eliminating vertical transmission

- % coverage for family planning (among all women)
- % pregnant women booking antenatal appointments before 12 weeks’ gestation
- % pregnant women attending at least eight antenatal visits
- % HIV testing coverage among pregnant women
- % pregnant women having institutional deliveries
- % ART re-testing coverage among pregnant women without HIV at delivery
- % ART coverage among pregnant or breastfeeding women with HIV
- % viral suppression among pregnant or breastfeeding women with HIV taking ART

1. Health Systems Research Unit, South African Medical Research Council, South Africa
2. Department of Paediatrics, University of Pretoria, Pretoria, South Africa
3. School of Public Health, University of the Western Cape, Cape Town, South Africa
4. Health Section, Unicef, New York, USA
5. National Department of Health, Pretoria, South Africa
6. Health Section, Unicef South Africa, Pretoria, South Africa
7. Data and Analytics Section, Unicef, New York, USA
8. Unicef Office of Research, Innocenti, Florence, Italy

Correspondence to: A Goga Ameena.Goga@mrc.ac.za

OPEN ACCESS

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

The BMJ: first published as 10.1136/bmj.l687 on 26 March 2019. Downloaded from http://www.bmj.com on 30 March 2019 by guest. Protected by copyright.